203 related articles for article (PubMed ID: 38831433)
21. Plasma lipid levels and risk of retinal vascular occlusion: A genetic study using Mendelian randomization.
Zheng C; Lin Y; Jiang B; Zhu X; Lin Q; Luo W; Tang M; Xie L
Front Endocrinol (Lausanne); 2022; 13():954453. PubMed ID: 36299452
[TBL] [Abstract][Full Text] [Related]
22. Genetically-predicted life-long lowering of low-density lipoprotein cholesterol is associated with decreased frailty: A Mendelian randomization study in UK biobank.
Wang Q; Wang Y; Lehto K; Pedersen NL; Williams DM; Hägg S
EBioMedicine; 2019 Jul; 45():487-494. PubMed ID: 31300347
[TBL] [Abstract][Full Text] [Related]
23. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
Ference BA; Majeed F; Penumetcha R; Flack JM; Brook RD
J Am Coll Cardiol; 2015 Apr; 65(15):1552-61. PubMed ID: 25770315
[TBL] [Abstract][Full Text] [Related]
24. The Relationship between Blood Lipids and Risk of Atrial Fibrillation: Univariable and Multivariable Mendelian Randomization Analysis.
Yang S; Pudasaini R; Zhi H; Wang L
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35011056
[TBL] [Abstract][Full Text] [Related]
25. Genetically instrumented LDL-cholesterol lowering and multiple disease outcomes: A Mendelian randomization phenome-wide association study in the UK Biobank.
Pham K; Mulugeta A; Lumsden A; Hyppӧnen E
Br J Clin Pharmacol; 2023 Oct; 89(10):2992-3004. PubMed ID: 37208559
[TBL] [Abstract][Full Text] [Related]
26. Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
Lotta LA; Stewart ID; Sharp SJ; Day FR; Burgess S; Luan J; Bowker N; Cai L; Li C; Wittemans LBL; Kerrison ND; Khaw KT; McCarthy MI; O'Rahilly S; Scott RA; Savage DB; Perry JRB; Langenberg C; Wareham NJ
JAMA Cardiol; 2018 Oct; 3(10):957-966. PubMed ID: 30326043
[TBL] [Abstract][Full Text] [Related]
27. Role of Blood Lipids in the Development of Ischemic Stroke and its Subtypes: A Mendelian Randomization Study.
Hindy G; Engström G; Larsson SC; Traylor M; Markus HS; Melander O; Orho-Melander M;
Stroke; 2018 Apr; 49(4):820-827. PubMed ID: 29535274
[TBL] [Abstract][Full Text] [Related]
28. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes.
White J; Swerdlow DI; Preiss D; Fairhurst-Hunter Z; Keating BJ; Asselbergs FW; Sattar N; Humphries SE; Hingorani AD; Holmes MV
JAMA Cardiol; 2016 Sep; 1(6):692-9. PubMed ID: 27487401
[TBL] [Abstract][Full Text] [Related]
29. Assessing the Impact of PCSK9 and HMGCR Inhibition on Liver Function: Drug-Target Mendelian Randomization Analyses in Four Ancestries.
Rosoff DB; Bell AS; Wagner J; Mavromatis LA; Hamandi A; Park L; Jung J; Lohoff FW
Cell Mol Gastroenterol Hepatol; 2024; 17(1):29-40. PubMed ID: 37703945
[TBL] [Abstract][Full Text] [Related]
30. Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study.
Alghamdi J; Matou-Nasri S; Alghamdi F; Alghamdi S; Alfadhel M; Padmanabhan S
Int J Neuropsychopharmacol; 2018 Dec; 21(12):1067-1075. PubMed ID: 29986042
[TBL] [Abstract][Full Text] [Related]
31. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study.
Huang W; Xiao J; Ji J; Chen L
Elife; 2021 Dec; 10():. PubMed ID: 34866576
[TBL] [Abstract][Full Text] [Related]
32. Associations of lipids and lipid-modifying drug target genes with atrial fibrillation risk based on genomic data.
Tao Y; Wang Y; Yin Y; Zhang K; Gong Y; Ying H; Jiang R
Lipids Health Dis; 2024 Jun; 23(1):175. PubMed ID: 38851763
[TBL] [Abstract][Full Text] [Related]
33. Causal relationship between PCSK9 inhibitor and primary glomerular disease: a drug target Mendelian randomization study.
Duan H; Shi Y; Zhang Q; Shi X; Zhang Y; Liu J; Zhang Y
Front Endocrinol (Lausanne); 2024; 15():1335489. PubMed ID: 38510702
[TBL] [Abstract][Full Text] [Related]
34. Effect of blood lipids and lipid-lowering therapies on osteoarthritis risk: A Mendelian randomization study.
Wang Z; Liu M; Zhou Y; Shao H; Yang D; Huang Y; Deng W
Front Med (Lausanne); 2022; 9():990569. PubMed ID: 36438033
[TBL] [Abstract][Full Text] [Related]
35. Association of lipid-lowering drugs with osteoarthritis outcomes from a drug-target Mendelian randomization study.
Ma W; Chen H; Zhang Z; Xiong Y
PLoS One; 2024; 19(2):e0293960. PubMed ID: 38416763
[TBL] [Abstract][Full Text] [Related]
36. Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations.
Ardissino M; Slob EAW; Reddy RK; Morley AP; Schuermans A; Hill P; Williamson C; Honigberg MC; de Marvao A; Ng FS
Eur J Prev Cardiol; 2024 Jun; 31(8):955-965. PubMed ID: 38294056
[TBL] [Abstract][Full Text] [Related]
37. Exploring the Role of Plasma Lipids and Statin Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study.
Almramhi MM; Finan C; Storm CS; Schmidt AF; Kia DA; Coneys R; Chopade S; Hingorani AD; Wood NW
Neurology; 2023 Oct; 101(17):e1729-e1740. PubMed ID: 37657941
[TBL] [Abstract][Full Text] [Related]
38. Identification of lipid-modifying drug targets for autoimmune diseases: insights from drug target mendelian randomization.
Hu X; Zhang P; Gao Y; Ding WW; Cheng XE; Shi QQ; Li S; Zhu YY; Pan HF; Wang P
Lipids Health Dis; 2024 Jun; 23(1):193. PubMed ID: 38909219
[TBL] [Abstract][Full Text] [Related]
39. Lipids and sudden sensorineural hearing loss: A bidirectional two-sample Mendelian randomization analysis.
Pu K; Li L; Qiu Y; Song H
Auris Nasus Larynx; 2024 Apr; 51(2):365-370. PubMed ID: 37993362
[TBL] [Abstract][Full Text] [Related]
40. HDL Cholesterol, LDL Cholesterol, and Triglycerides as Risk Factors for CKD: A Mendelian Randomization Study.
Lanktree MB; Thériault S; Walsh M; Paré G
Am J Kidney Dis; 2018 Feb; 71(2):166-172. PubMed ID: 28754456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
